Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of adverse outcomes in the UK PANORAMIC trial: an economic evaluation of the PANORAMIC trial
Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of adverse outcomes in the UK PANORAMIC trial: an economic evaluation of the PANORAMIC trial
Background: the cost-effectiveness of molnupiravir, an oral antiviral for early treatment of SARS-CoV-2, has not been established in vaccinated populations.
Aim: to evaluate the cost-effectiveness of molnupiravir relative to usual care alone among mainly vaccinated community-based people at higher risk of severe outcomes from COVID-19 over six months.
Design and setting: economic evaluation of the PANORAMIC trial in the UK.
Method: a cost-utility analysis that adopted a UK National Health Service and personal social services perspective and a six-month time horizon was performed using PANORAMIC trial data. Cost-effectiveness was expressed in terms of incremental cost per quality-adjusted life year (QALY) gained. Sensitivity and subgroup analyses assessed the impacts of uncertainty and heterogeneity. Threshold analysis explored the price for molnupiravir consistent with likely reimbursement.
Results: in the base case analysis, molnupiravir had higher mean costs of £449 (95% confidence interval [CI] 445 to 453) and higher mean QALYs of 0.0055 (95% CI 0.004 to 0.007) than usual care (mean incremental cost per QALY of £81190). Sensitivity and subgroup analyses showed similar results, except those aged ≥75 years with a 55% probability of being cost-effective at a £30000 per QALY threshold. Molnupiravir would have to be priced around £147 per course to be cost-effective at a £15000 per QALY threshold.
Conclusion: molnupiravir at the current cost of £513 per course is unlikely to be cost-effective relative to usual care over a six-month time horizon among mainly vaccinated COVID-19 patients at increased risk of adverse outcomes, except those aged ≥75 years.
Adult, Antiviral Agents/economics, COVID-19 Drug Treatment, COVID-19/prevention & control, Cost-Benefit Analysis, Cytidine/analogs & derivatives, Female, Humans, Hydroxylamines/therapeutic use, Male, Middle Aged, Quality-Adjusted Life Years, SARS-CoV-2, United Kingdom
e570-e579
Png, May Ee
ebb739c2-b3ab-483c-8d5a-1cef01799afa
Harris, Victoria
b6d6e7b3-9a3b-48ea-a506-aa6716d5f973
Grabey, Jenna
ae75693d-6da5-4834-bdcb-771ec029c256
Hart, Nigel David
54bd7c70-5505-4aa8-8997-8397149500b0
Jani, Bhautesh Dinesh
9f519f10-405c-44e5-bf8d-722a4dad24ad
Butler, Daniel
8172594e-49d9-4ac1-8a76-f481459bd35e
Carson-Stevens, Andrew
d34901f8-fbac-4921-8bf2-dfb1fe81512b
Coates, Maria
4bece266-f962-40a0-8289-cfa22c3a9d1c
Cureton, Lucy
5ac89f43-805b-4973-b303-a0b017e667b0
Dobson, Melissa
30b8369c-22ae-41b4-8747-8e83181b3585
Dorward, Jienchi
4bf66901-771f-4d52-bb9d-bf3fda2fb272
Evans, Philip
7bd91706-f249-471d-be68-e1a33d95b6b6
Francis, Nick
9b610883-605c-4fee-871d-defaa86ccf8e
Gbinigie, Oghenekome Abisoye
8d4ff434-0535-4f56-8465-feccafe1247b
Hayward, Gail
91362d6f-3c3b-4eae-8fc8-1571ccf184c1
Holmes, Jane
cae8db15-fb4a-473f-a5f8-5008dc4c8991
Hood, Kerenza
dbabde72-de16-41ed-80e6-ad91791469ab
Khoo, Saye
4ad67fee-e6a4-43d2-b7a8-5920d718f568
Ahmed, Haroon
880dac61-6070-4e31-9d09-ed7dbbf9a5cf
Lown, Mark
4742d5f8-bcf3-4e0b-811c-920e7d010c9b
Mckenna, Micheal
c29c18b6-7563-402d-90e5-1020806eb903
Mort, Sam
d88c662b-4f32-41d2-b11f-560f8e0ea6ff
Nguyen-Van-Tam, Jonathan
489ea2ed-2c0b-435b-88f1-ebfaffed800f
Rahman, Najib
16ffac72-7f1b-4ae1-9641-2ed9a96c71d8
Richards, Duncan B
b9c1e85c-05e6-48c9-86c6-566602955af0
Thomas, Nicholas
1218f8d6-787a-4b0a-9603-7c831563a9d7
van Hecke, Oliver
2e5330f6-842a-4b1e-9f89-f30dabe4580f
Hobbs, Fd Richard
2e48ac78-1c66-4738-844b-a0ea0cb85d6f
Little, Paul
1bf2d1f7-200c-47a5-ab16-fe5a8756a777
Yu, Ly-Mee
bc6ca332-bffb-4836-80e9-c427dca12c19
Butler, Christopher C
8bf4cace-c34a-4b65-838f-29c2be91e434
Petrou, Stavros
5ee930f5-99db-4fb8-b401-95584cff0e20
August 2024
Png, May Ee
ebb739c2-b3ab-483c-8d5a-1cef01799afa
Harris, Victoria
b6d6e7b3-9a3b-48ea-a506-aa6716d5f973
Grabey, Jenna
ae75693d-6da5-4834-bdcb-771ec029c256
Hart, Nigel David
54bd7c70-5505-4aa8-8997-8397149500b0
Jani, Bhautesh Dinesh
9f519f10-405c-44e5-bf8d-722a4dad24ad
Butler, Daniel
8172594e-49d9-4ac1-8a76-f481459bd35e
Carson-Stevens, Andrew
d34901f8-fbac-4921-8bf2-dfb1fe81512b
Coates, Maria
4bece266-f962-40a0-8289-cfa22c3a9d1c
Cureton, Lucy
5ac89f43-805b-4973-b303-a0b017e667b0
Dobson, Melissa
30b8369c-22ae-41b4-8747-8e83181b3585
Dorward, Jienchi
4bf66901-771f-4d52-bb9d-bf3fda2fb272
Evans, Philip
7bd91706-f249-471d-be68-e1a33d95b6b6
Francis, Nick
9b610883-605c-4fee-871d-defaa86ccf8e
Gbinigie, Oghenekome Abisoye
8d4ff434-0535-4f56-8465-feccafe1247b
Hayward, Gail
91362d6f-3c3b-4eae-8fc8-1571ccf184c1
Holmes, Jane
cae8db15-fb4a-473f-a5f8-5008dc4c8991
Hood, Kerenza
dbabde72-de16-41ed-80e6-ad91791469ab
Khoo, Saye
4ad67fee-e6a4-43d2-b7a8-5920d718f568
Ahmed, Haroon
880dac61-6070-4e31-9d09-ed7dbbf9a5cf
Lown, Mark
4742d5f8-bcf3-4e0b-811c-920e7d010c9b
Mckenna, Micheal
c29c18b6-7563-402d-90e5-1020806eb903
Mort, Sam
d88c662b-4f32-41d2-b11f-560f8e0ea6ff
Nguyen-Van-Tam, Jonathan
489ea2ed-2c0b-435b-88f1-ebfaffed800f
Rahman, Najib
16ffac72-7f1b-4ae1-9641-2ed9a96c71d8
Richards, Duncan B
b9c1e85c-05e6-48c9-86c6-566602955af0
Thomas, Nicholas
1218f8d6-787a-4b0a-9603-7c831563a9d7
van Hecke, Oliver
2e5330f6-842a-4b1e-9f89-f30dabe4580f
Hobbs, Fd Richard
2e48ac78-1c66-4738-844b-a0ea0cb85d6f
Little, Paul
1bf2d1f7-200c-47a5-ab16-fe5a8756a777
Yu, Ly-Mee
bc6ca332-bffb-4836-80e9-c427dca12c19
Butler, Christopher C
8bf4cace-c34a-4b65-838f-29c2be91e434
Petrou, Stavros
5ee930f5-99db-4fb8-b401-95584cff0e20